Despite recent advances in the systemic treatment of extracranial metastases by using BRAF-targeted therapy in patients harboring BRAFV600E-mutant melanomas or inhibitors targeting immune checkpoint molecules, the treatment of melanoma brain metastases remains a major challenge. This evidence concerns the gene BRAF and melanoma.